Market Place
Sourcing Support
Santhera Signs Supply Deal for Vamorolone with Ali Al Suwaidi
12 Nov 2024 //
GLOBENEWSWIRE
Santhera Reports Positive Results From LIONHEART Study
01 Oct 2024 //
GLOBENEWSWIRE
Swissmedic Accepts Santhera`s AGAMREE Marketing Application
23 Sep 2024 //
GLOBENEWSWIRE
Santhera Announces H1 2024 Results And Corporate Update
12 Sep 2024 //
GLOBENEWSWIRE
Santhera Enters Distribution Agreement With GENESIS Pharma
10 Sep 2024 //
GLOBENEWSWIRE
Santhera Secures Funding To Reach Break-Even Expected In 2026
12 Aug 2024 //
GLOBENEWSWIRE
Santhera Appoints Oliver Kronenberg As Chief Legal Officer
31 Jul 2024 //
GLOBENEWSWIRE
Santhera Secures Up To CHF 69M In Royalty And Debt Financing
18 Jun 2024 //
GLOBENEWSWIRE
Santhera`s Shareholders Approve All Proposals At AGM
18 Jun 2024 //
GLOBENEWSWIRE
Pfizer`s Setback In DMD Trial Clears Path For Sarepta And Others | DelveInsight
17 Jun 2024 //
PR NEWSWIRE
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
11 Jun 2024 //
PHARMAFILE
Santhera Launches China Early Access For AGAMREE Via Sperogenix
10 Jun 2024 //
GLOBENEWSWIRE
Santhera Publishes Annual Report 2023
28 May 2024 //
GLOBENEWSWIRE
Santhera Publishes Agenda for its Annual General Meeting
28 May 2024 //
GLOBENEWSWIRE
Santhera Announces NDA for vamorolone in DMS Accepted and GPR by China
27 Mar 2024 //
GLOBENEWSWIRE
Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States
14 Mar 2024 //
GLOBENEWSWIRE
Santhera Announces Publication of Efficacy and Tolerability Data with Vamorolone
14 Feb 2024 //
GLOBENEWSWIRE
Santhera Launches AGAMREE in Germany as First Market for DMD
16 Jan 2024 //
GLOBENEWSWIRE
Santhera Receives Approval for AGAMREE as a Treatment for DMD
12 Jan 2024 //
GLOBENEWSWIRE
Santhera’s Agamree gains EU approval for Duchenne muscular dystrophy
19 Dec 2023 //
GLOBENEWSWIRE
Santhera Appoints Committee Members as it Transitions into Commercial Stage
07 Dec 2023 //
GLOBENEWSWIRE
Santhera`s drug gets US FDA nod for rare muscular dystrophy
27 Oct 2023 //
GLOBENEWSWIRE
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE
13 Oct 2023 //
GLOBENEWSWIRE
Santhera Announces Half-Year 2023 Financial Results & Provides Corporate Update
07 Sep 2023 //
GLOBENEWSWIRE
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
31 Jul 2023 //
GLOBENEWSWIRE
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
31 Jul 2023 //
GLOBENEWSWIRE
Santhera Announces Closing of Agreement with Catalyst for Vamorolone
19 Jul 2023 //
GLOBENEWSWIRE
Santhera Publishes Timeline of the Reverse Share Split
29 Jun 2023 //
GLOBENEWSWIRE
Shareholders Approve all Board Proposals at Today™s Annual General Meeting
27 Jun 2023 //
GLOBENEWSWIRE
Catalyst to License North American Rights to Vamorolone for DMD from Santhera
20 Jun 2023 //
GLOBENEWSWIRE
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
20 Jun 2023 //
PHARMAFILE
Santhera offloads North American rights for DMD med to Catalyst
20 Jun 2023 //
FIERCE BIOTECH
Santhera Grants Exclusive North America License for Vamorolone to Catalyst
20 Jun 2023 //
GLOBENEWSWIRE
Santhera Publishes Agenda for its Annual General Meeting
06 Jun 2023 //
GLOBENEWSWIRE
Santhera Publishes Annual Report 2022
31 May 2023 //
GLOBENEWSWIRE
Santhera Announces Preliminary Unaudited 2022 Annual Results
27 Apr 2023 //
GLOBENEWSWIRE
Vamorolone NDA mid-cycle review meeting by FDA completed
25 Apr 2023 //
GLOBENEWSWIRE
Santhera Submits MAA to the UK MHRA for Vamorolone
02 Mar 2023 //
GLOBENEWSWIRE
Santhera Secures Funding Through a Private Placement of Shares
28 Feb 2023 //
GLOBENEWSWIRE
Santhera Concludes Agreement with French Authorities on Raxone Reimbursement
08 Feb 2023 //
GLOBENEWSWIRE
Santhera enters into CHF 5 million share exchange agreement
10 Jan 2023 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce FDA Acceptance of NDA for Vamorolone
09 Jan 2023 //
GLOBENEWSWIRE
Santhera lays out options in bid for commercialization funds
04 Nov 2022 //
ENDPTS
EMA Validates Santhera’s Marketing Authorization Application for Vamorolone
31 Oct 2022 //
GLOBENEWSWIRE
Santhera loses interest in pulmonary drug to focus on DMD
31 Oct 2022 //
FIERCEBIOTECH
Penny stock forges ahead with an NDA for Duchenne, seeking priority review
28 Oct 2022 //
ENDPTS
Santhera seeks speedy FDA review of Duchenne drug vamorolone
28 Oct 2022 //
PHARMAPHORUM
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone
27 Oct 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce Presentations on Efficacy and Bone Health in DMD
10 Oct 2022 //
GLOBENEWSWIRE
Santhera Submits Marketing Authorization Application to the EMAyfor Vamorolone
03 Oct 2022 //
GLOBENEWSWIRE
Santhera submits marketing authorisation application for vamorolone
03 Oct 2022 //
PHARMATIMES
Santhera Announces Preliminary 2022 Half-year FY Ahead of Full Report
29 Sep 2022 //
GLOBENEWSWIRE
JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone
31 Aug 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen Announce 1st Participant Dosed in FDA-funded PII study
22 Aug 2022 //
GLOBENEWSWIRE
Santhera`s Shareholders Approve all Board Proposals at Today`s AGM
30 Jun 2022 //
GLOBENEWSWIRE
Santhera sidelined by manufacturing delay for DMD drug
30 Jun 2022 //
FIERCEBIOTECH
Santhera Updates on Ongoing NDA Submission for Vamorolone
28 Jun 2022 //
GLOBENEWSWIRE
Santhera Nominates Thomas Meier to Succeed Elmar Schnee as Chairman of Board
27 Jun 2022 //
GLOBENEWSWIRE
Santhera Reports 2021 Annual Results
09 Jun 2022 //
GLOBENEWSWIRE
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 PPMDC
09 Jun 2022 //
GLOBENEWSWIRE
